t7 endonuclease i t7ei enzyme (New England Biolabs)
New England Biolabs is a verified supplier 
New England Biolabs manufactures this product 
99
Structured Review
New England Biolabs
t7 endonuclease i t7ei enzyme
T7 Endonuclease I T7ei Enzyme, supplied by New England Biolabs, used in various techniques. Bioz Stars score: 99/100, based on 2708 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/t7ei/T7+Endonuclease+I/pmc13650124-349-0-20
Average 99 stars, based on 2708 article reviews
T7 Endonuclease I T7ei Enzyme, supplied by New England Biolabs, used in various techniques. Bioz Stars score: 99/100, based on 2708 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/t7ei/T7+Endonuclease+I/pmc13650124-349-0-20
Average 99 stars, based on 2708 article reviews
t7 endonuclease i t7ei enzyme - by Bioz Stars,
2026-10
99/100 stars
Images
1) Product Images from "CD73 disruption with tumor-specific CRISPR/Cas9 nanoparticles reduces adenosine-mediated immunosuppression and amplifies response to chemotherapy"
Article Title: CD73 disruption with tumor-specific CRISPR/Cas9 nanoparticles reduces adenosine-mediated immunosuppression and amplifies response to chemotherapy
Journal: Nature Communications
doi: 10.1038/s41467-026-77547-4
Figure Legend Snippet: a Size distribution of iRGD-DC@CaP as determined by dynamic light scattering, and morphology of iRGD-DC@CaP as revealed by TEM images. Scale bar: 200 nm. b , c DOX and Cas9 release from iRGD-DC@CaP under different situations ( n = 3 biologically independent samples). Representative flow cytometry analysis images ( d ) and quantitative analysis ( e ) of cellular uptake in B16F10 cells following a 4 h incubation with iRGD-DC@CaP or controls ( n = 3 biologically independent samples). f Confocal laser scanning microscopy images of B16F10 cells following a 4 h incubation with iRGD-DC@CaP or controls. Cas9 was labeled with Alexa Fluor 647 (AF647; red), and the nuclei were stained with DAPI (blue). Scale bars: 50 µm. T7EI assay ( g ) and quantitative analysis ( h ) of indel frequencies of the Nt5e gene in B16F10 cells transfected with iRGD-DC CD73 @CaP or controls for 48 h ( n = 3 biologically independent samples). i Mutation rates of Nt5e examined by NGS analysis in B16F10 cells treated with iRGD-DC CD73 @CaP. j , k Western blot ( j ) and flow cytometry quantitative analysis ( k ) of CD73 protein expression in B16F10 cells after 72 h incubation with iRGD-DC CD73 @CaP or controls ( n = 3 biologically independent samples). l The ADO contents in the cell medium of B16F10 cells after 72 h incubation with iRGD-DC CD73 @CaP or controls detected by ELISA kits ( n = 3 biologically independent samples). The experiments for f and i were independently repeated three times with similar results. Data is presented as the mean ± SD. Statistical difference was assessed in ( e , h , j , k and l ) using one-way ANOVA with Dunnett’s multiple comparison test by comparing the iRGD-DC CD73 @CaP group with each of the other treatment groups. * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001. G1: saline (negative control); G2: Free Cas9 RNP; G3: iRGD-modified nanoparticles loaded with scrambled sgRNA (iRGD-DC Scr @CaP, negative control); G4: Lipofectamine™ CRISPRMAX™-mediated delivery of Cas9/sgCD73 (MAX Cas9/sgCD73, positive control); G5: nanoparticle without iRGD loaded with Cas9/sgCD73 (DC CD73 @CaP); G6: iRGD-modified nanoparticle loaded with Cas9/sgCD73 (iRGD-DC CD73 @CaP). The exact P value and Source data are provided as a Source Data file.
Techniques Used: Dynamic Light Scattering Assay, Morphology, Flow Cytometry, Analysis, Incubation, Confocal, Laser-Scanning Microscopy, Labeling, Staining, T7EI Assay, Transfection, Mutagenesis, Western Blot, Expressing, Enzyme-linked Immunosorbent Assay, Comparison, Saline, Negative Control, Modification, Positive Control
Figure Legend Snippet: a Fluorescence imaging of B16F10 tumor-bearing C57BL/6 mice following injection of iRGD-DC@CaP and controls ( n = 3 mice). b Quantitative analysis of AF647-Cas9 fluorescence from major organs in mice bearing B16F10 at 1 h after intravenous injection of iRGD-DC@CaP or controls ( n = 3 mice). “% ID/g” represents the percentage of the injected dose per gram of tissue. The exact P value: DC@CaP vs. iRGD-DC@CaP ** P = 0.0087. c Schematic illustration of B16F10 tumor therapy in vivo. Created in BioRender. Sun, X. (2026) https://BioRender.com/f4h4ymp . d Individual and average tumor growth curves of B16F10 following different treatments ( n = 5 mice). e Tumor weight and the tumor inhibition ratio following different treatments ( n = 5 mice). f Survival analysis of the mice following different treatments ( n = 6 mice). P values were determined by the log-rank test. g Indel frequency of Nt5e loci measured by T7EI assay in B16F10 tumor tissues with the indicated treatments. The experiment was independently repeated three times with similar results. h Western blotting and relative quantitative analysis of CD73 proteins in B16F10 tumor tissues with the indicated treatments ( n = 3 biologically independent samples). i The flow cytometry quantitative analysis of the CD73 expression on tumor cells (CD45 − ), endothelial cells (CD45 − CD31 + ), cancer-associated fibroblasts (CAFs) (CD45 − CD31 − GP38 + ), macrophages (CD45 + CD11b + F4/80 + ), DCs (CD45 + CD11c + MHC-II + ), Tregs (CD45 + CD4 + CD25 + Foxp3 + ) and MDSCs (CD45 + CD11b + Gr-1 + ) in B16F10 tumor tissues after indicated treatments ( n = 5 mice). j The ADO contents in the tumor after different treatments ( n = 5 mice). Data is presented as the mean ± SD. Statistical differences were assessed using one-way ANOVA in ( b , e , h , i and j ) or two-way ANOVA in ( d ) with Dunnett’s multiple comparison test by comparing the iRGD-DC CD73 @CaP group with each of the other treatment groups. * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001. G1: saline (negative control); G2: iRGD-modified nanoparticles loaded with scrambled sgRNA (iRGD-DC Scr @CaP, negative control); G3: iRGD-modified nanoparticle loaded with Cas9/sgCD73 (iRGD-DC CD73 @CaP). The exact P value and Source data are provided as a Source Data file.
Techniques Used: Fluorescence, Imaging, Injection, Analysis, Mouse Assay, Tissue, In Vivo, Inhibition, T7EI Assay, Western Blot, Flow Cytometry, Expressing, Comparison, Saline, Negative Control, Modification
Figure Legend Snippet: a Schematic illustration of experimental design for 4T1 tumor therapy in vivo. b , c Average ( b ) and individual ( c ) tumor growth curves of 4T1 following different treatments ( n = 5 mice). d Tumor weight and tumor inhibition ratio following different treatments ( n = 5 mice). e Survival analysis of the mice following different treatments ( n = 6 mice). f Indel frequency of Nt5e loci measured by T7EI assay in 4T1 tumor tissues with the indicated treatments. The experiment was independently repeated three times with similar results. g Western blot and relative quantitative analysis of CD73 protein expression in 4T1 tumor tissues with the indicated treatments ( n = 3 biologically independent samples). h The ADO contents in the tumor after different treatments ( n = 5 mice). i–t Flow cytometry quantitative analysis of CD80 + CD86 + DCs ( i ), absolute number of CD8 + T cells ( j ), CD3 + CD8 + T cells ( k ), CD4 + CD25 + Foxp3 + Tregs ( l ), CD8 + T/Tregs ratio ( m ), CD3 − CD49b + NK cells ( n ), F4/80 + CD86 + cells ( o ), F4/80 + iNOS + cells ( p ), F4/80 + CD206 + cells ( q ), F4/80 + Arg1 + cells ( r ), F4/80 + CD86 + M1/F4/80 + CD206 + M2 ratio ( s ), and CD11b + Gr-1 + MDSCs ( t ) in tumor after different treatments ( n = 5 mice). u–w Contents of the IL-2 ( u ), TNF-α ( v ), and IFN-γ ( w ) in tumor tissues after different treatments ( n = 5 mice). Data is presented as the mean ± SD. Statistical differences were analyzed by two-way ANOVA with Dunnett’s multiple comparison test in ( b ), one-way ANOVA with Dunnett’s multiple comparison test in ( d , g , and h–w ) by comparing the iRGD-DC CD73 @CaP group with each of the other treatment groups. * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001. G1: saline (negative control); G2: iRGD-modified nanoparticles loaded with scrambled sgRNA (iRGD-DC Scr @CaP, negative control); G3: iRGD-modified nanoparticle loaded with Cas9/sgCD73 (iRGD-DC CD73 @CaP). The exact P value and Source data are provided as a Source Data file.
Techniques Used: In Vivo, Inhibition, Analysis, T7EI Assay, Western Blot, Expressing, Flow Cytometry, Comparison, Saline, Negative Control, Modification
Related Articles
other:Article Title: Detection of CRISPR-Cas-induced mutations in Daphnia Article Snippet: In contrast, Article Title: Detection of CRISPR-Cas-induced mutations in Daphnia. Article Snippet: In contrast, Polymerase Chain Reaction:Article Title: Genome-wide CRISPR screen for human factors involved in alternative polyadenylation based on differential localization of CD47 Article Snippet: Target regions were amplified by PCR using KOD FX Neo (Toyobo). .. The re-annealed PCR products were incubated with Article Title: Stage- and tissue-specific gene editing using 4-OHT-inducible Cas9 in whole organism. Article Snippet: .. When detecting the target gene mutations in HEK293T cells, embryos, and cell mixtures, PCR products were further examined by Article Title: Mdfi Regulates Myoblast Proliferation and Cell Cycle Progression through Cyclins Article Snippet: The target region was amplified by PCR using gene-specific primers (Table S1) and 2× High-Fidelity PCR Master Mix (M0531, New England Biolabs, NEB, Ipswich, MA, USA). .. The T7 Endonuclease I (T7EI) assay was performed by incubating 200 ng of purified PCR product with 10 units of Article Title: Stage- and tissue-specific gene editing using 4-OHT–inducible Cas9 in whole organism Article Snippet: The genomes of PGC mixtures, individual PGCs, and individual mouse blastomeres were extracted and amplified with the Single Cell WGA Kit (N603; Vazyme), diluted with ddH 2 O to a suitable concentration, and used as PCR templates. summarizes the primer sequences for genotyping. .. When detecting the target gene mutations in HEK293T cells, embryos, and cell mixtures, PCR products were further examined by Article Title: CRISPR-Cas systems and uses thereof Article Snippet: .. Then, the mixture was treated with NEB buffer 2 containing salt ions and Incubation:Article Title: Genome-wide CRISPR screen for human factors involved in alternative polyadenylation based on differential localization of CD47 Article Snippet: Target regions were amplified by PCR using KOD FX Neo (Toyobo). .. The re-annealed PCR products were incubated with Electrophoresis:Article Title: Genome-wide CRISPR screen for human factors involved in alternative polyadenylation based on differential localization of CD47 Article Snippet: Target regions were amplified by PCR using KOD FX Neo (Toyobo). .. The re-annealed PCR products were incubated with Sequencing:Article Title: Stage- and tissue-specific gene editing using 4-OHT-inducible Cas9 in whole organism. Article Snippet: .. When detecting the target gene mutations in HEK293T cells, embryos, and cell mixtures, PCR products were further examined by Article Title: Stage- and tissue-specific gene editing using 4-OHT–inducible Cas9 in whole organism Article Snippet: The genomes of PGC mixtures, individual PGCs, and individual mouse blastomeres were extracted and amplified with the Single Cell WGA Kit (N603; Vazyme), diluted with ddH 2 O to a suitable concentration, and used as PCR templates. summarizes the primer sequences for genotyping. .. When detecting the target gene mutations in HEK293T cells, embryos, and cell mixtures, PCR products were further examined by T7EI Assay:Article Title: Mdfi Regulates Myoblast Proliferation and Cell Cycle Progression through Cyclins Article Snippet: The target region was amplified by PCR using gene-specific primers (Table S1) and 2× High-Fidelity PCR Master Mix (M0531, New England Biolabs, NEB, Ipswich, MA, USA). .. The T7 Endonuclease I (T7EI) assay was performed by incubating 200 ng of purified PCR product with 10 units of Purification:Article Title: Mdfi Regulates Myoblast Proliferation and Cell Cycle Progression through Cyclins Article Snippet: The target region was amplified by PCR using gene-specific primers (Table S1) and 2× High-Fidelity PCR Master Mix (M0531, New England Biolabs, NEB, Ipswich, MA, USA). .. The T7 Endonuclease I (T7EI) assay was performed by incubating 200 ng of purified PCR product with 10 units of Agarose Gel Electrophoresis:Article Title: CRISPR-Cas systems and uses thereof Article Snippet: .. Then, the mixture was treated with NEB buffer 2 containing salt ions and |